Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present IntelGenx Technologies Corp. (OTC: IGXT).

Full DD Report for IGXT

You must become a subscriber to view this report.


Recent News from (OTC: IGXT)

IntelGenx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
SAINT LAURENT, Quebec, Aug. 30, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today announced that its Chief Financial Officer, Andre Godin, is scheduled to present at the Rodman & Renshaw 20th A...
Source: GlobeNewswire
Date: August, 30 2018 08:00
IntelGenx Technologies' (IGXT) CEO Horst Zerbe on Q2 2018 Results - Earnings Call Transcript
IntelGenx Technologies Corporation (IGXT) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET Executives Stephen Kilmer – Investor Relations Horst Zerbe – President and Chief Executive Officer Andre Godin – Executive Vice President and Chief Financial ...
Source: SeekingAlpha
Date: August, 10 2018 14:54
IntelGenx Reports Second Quarter 2018 Financial Results
SAINT LAURENT, Quebec, Aug. 09, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the second quarter ended June 30, 2018. All dollar amounts are expressed in U.S. cur...
Source: GlobeNewswire
Date: August, 09 2018 16:16
IntelGenx to Report Second Quarter 2018 Financial Results on Aug 9, 2018 - Conference Call to Follow
SAINT LAURENT, Quebec, Aug. 02, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its second quarter 2018 financial results after market close on Aug 9, 2018. An accompanying conference call will be hosted ...
Source: GlobeNewswire
Date: August, 02 2018 16:00
Alzheimer's players in the green on Biogen news
Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: July, 06 2018 10:12
IntelGenx Receives CIPO Notice of Allowance for Loxapine VersaFilm(TM) Patent
SAINT LAURENT, Quebec, July 05, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) (“IntelGenx” or the “Company”), a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films ba...
Source: GlobeNewswire
Date: July, 05 2018 08:00
IntelGenx Announces Notice of Grant of European Patent Covering  Rizaport® VersaFilm(TM)
SAINT LAURENT, Quebec, June 19, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today announced that the European Patent Office (“EPO”) has issued a “Notice of Intention to Grant” for th...
Source: GlobeNewswire
Date: June, 19 2018 08:00
IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures
SAINT LAURENT, Quebec, June 14, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “ Company ” or “ IntelGenx ”) announces that it intends to issue 307,070 common shares of the Corporation (the “ Common Shares ”) at ...
Source: GlobeNewswire
Date: June, 14 2018 08:03
Article in Alzheimer's & Dementia Points to an Additional Unmet Medical Need Targeted by IntelGenx' Montelukast VersaFilm(TM)
SAINT LAURENT, Quebec, June 06, 2018 (GLOBE NEWSWIRE) --  IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today announced that a peer-reviewed paper entitled “2018 Alzheimer’s Disease Facts and Figures,” publi...
Source: GlobeNewswire
Date: June, 06 2018 08:00
Performance and Restricted Share Unit Plan Approved by IntelGenx Technologies Corp. Shareholders
SAINT LAURENT, Quebec, May 15, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) confirms that the shareholders of the Company (the “Shareholders”) approved the implementation of the Perfor...
Source: GlobeNewswire
Date: May, 15 2018 17:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-170.600.5370.600.53111,840
2018-12-140.5550.5560.5560.515360,822
2018-12-130.5550.5460.5550.53282,300
2018-12-120.570.5450.58670.5401199,380
2018-12-110.5650.570.60880.55344,602

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1732,610111,84029.1577Cover
2018-12-14128,875345,82237.2663Short
2018-12-1376,250269,30028.3141Cover
2018-12-12113,541199,38056.9470Short
2018-12-1172,675344,60221.0895Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IGXT.


About IntelGenx Technologies Corp. (OTC: IGXT)

Logo for IntelGenx Technologies Corp. (OTC: IGXT)

IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies. Established in , the Montreal based company develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilmTM, VersaTabTM and AdVersaTM. IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XLTM, launched in , is the first and only FDA approved once daily bupropion HCl mg dose in a single tablet for the treatment of major depressive disorder. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R amp D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state of the art manufacturing facility, established for the VersaFilmTM technology platform, supports lab scale to pilot and commercial scale production, offering full service capabilities to our clients. IntelGenx Technologies Corp. is listed on the TSX V and OTC QX, More information is available about the company at: www.intelgenx.com.

 

Contact Information

 

 

Current Management

  • Horst G. Zerbe, Ph.D / CEO, President
  • Ingrid Zerbe / Corporate Secretary
  • Horst G. Zerbe, Ph.D / Chairman, Nominating Committee Member
  • J. Bernard Boudreau / Vice Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • John Marinucci / Independent Director, Audit Committee Member, Compensation Committee Member
  • Clemens Mayr / Compensation Committee Member, Nominating Committee Member
  • Bernd J. Melchers / Independent Director, Audit Committee Member
  • Mark Nawacki / Nominating Committee Member
  • Ian John Troup / Independent Director, Audit Committee Member, Compensation Committee Member

Current Share Structure

  • Market Cap: $45,843,370 - 03/09/2018
  • Authorized: 200,000,000 - 05/11/2017
  • Issue and Outstanding: 66,931,467 - 09/30/2017
  • Float: 56,349,866 - 01/26/2017

 


Recent Filings from (OTC: IGXT)

Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: May, 17 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 16 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: April, 06 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 29 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (OTC: IGXT)

Daily Technical Chart for (OTC: IGXT)


Stay tuned for daily updates and more on (OTC: IGXT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IGXT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IGXT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IGXT and does not buy, sell, or trade any shares of IGXT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/